Codis Acquires Catalent's Nottingham Facility, Expands European Spray Dry Network
Codis has completed the acquisition of Catalent's facility in Nottingham, UK, expanding its European spray dry network and adding oral solid dose development and small-scale commercial manufacturing capabilities.
Codis announced the completion of its acquisition of Catalent's manufacturing facility located in Nottingham, United Kingdom. This strategic move broadens Codis' European spray drying network and incorporates capabilities in oral solid dose development and small-scale commercial manufacturing.
The Nottingham site brings over two decades of expertise in formulation development and clinical supply. The integration of this team and its experience into Codis is expected to enhance the company's ability to serve clients across Europe with a more comprehensive suite of services.
The acquisition aims to bolster Codis' integrated spray dry offering within the European market. The company intends to leverage the new capabilities to provide a wider range of solutions for pharmaceutical development and manufacturing needs, catering to various dosage forms.
Codis positions this acquisition as a step towards strengthening its role as a contract development and manufacturing organization (CDMO). The expansion is intended to solidify its market presence and operational capacity within the European pharmaceutical sector.